SCHEMBL2824816

SCHEMBL2824816

CC1(C)C(=O)N(CC(N)=O)c2cc(Br)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
TP53 P04637 4/20 0.41
ANPEP P15144 3/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
THRB P10828 2/20 0.39
POLB P06746 1/20 0.39
S100A4 P26447 1/20 0.39
BRCA1 P38398 1/20 0.39
RECQL P46063 1/20 0.39
CUL4A Q13619 1/20 0.38
ALDH1A1 P00352 3/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17275707 0.81 ALDH1A1 (0.47) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL14732125 0.76 KMT2A (0.41) MAPTTP53LMNAKMT2AMEN1
SCHEMBL26756233 0.76 CUL4A (0.55) MAPTTP53ANPEPLMNAKMT2A
SCHEMBL26640052 0.76 ANPEP (0.49) MAPTTP53ANPEPLMNAKMT2A
SCHEMBL30224652 0.76 BACE1 (0.38) MAPTTP53ANPEPLMNAKMT2A
SCHEMBL23992898 0.76 BACE1 (0.38) MAPTTP53ANPEPLMNAKMT2A
SCHEMBL30642207 0.76 ANPEP (0.49) MAPTTP53ANPEPLMNAKMT2A
SCHEMBL22122205 0.76 MAPT (0.38) MAPTTP53LMNAKMT2AMEN1
SCHEMBL22122204 0.76 MAPT (0.38) MAPTTP53LMNAKMT2AMEN1
SCHEMBL31411532 0.75 ELANE (0.58) MAPTTP53LMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799643-B1 INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-7632856-B2 Indolone derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2009-12-15 US disclosed
US-20090012147-A1 Indolone Derivatives, Processes For Preparing Them And Their Uses UCB PHARMA, S.A. (BE) 2009-01-08 US disclosed
EP-1799643-A1 INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2007-06-27 EP disclosed
WO-2006008067-A1 INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-01-26 WO disclosed
US-5514690-A Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline E. R. SQUIBB & SONS, INC. (US) 1996-05-07 US disclosed
EP-0610553-A1 Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline E.R. SQUIBB & SONS, INC. (US) 1994-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012147-A1 Indolone Derivatives, Processes For Preparing Them And Their Uses IDO1, IDO2, HTR3C MAPT 593/4885TP53 2871/4885ANPEP 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.